APA (7th ed.) Citation

Guerini, A. E., Pedretti, S., Carlino, A., Maddalo, M., Mataj, E., Pegurri, L., . . . Buglione di Monale e Bastia, M. (2026). CDK4/6 Inhibition and Stereotactic Radiotherapy in Oligometastatic HR+/HER2− Breast Cancer: Evidence of Immunogenic Modulation and Pseudoprogression. Immuno, 6(2), 40. https://doi.org/10.3390/immuno6020040

Chicago Style (17th ed.) Citation

Guerini, Andrea Emanuele, et al. "CDK4/6 Inhibition and Stereotactic Radiotherapy in Oligometastatic HR+/HER2− Breast Cancer: Evidence of Immunogenic Modulation and Pseudoprogression." Immuno 6, no. 2 (2026): 40. https://doi.org/10.3390/immuno6020040.

MLA (9th ed.) Citation

Guerini, Andrea Emanuele, et al. "CDK4/6 Inhibition and Stereotactic Radiotherapy in Oligometastatic HR+/HER2− Breast Cancer: Evidence of Immunogenic Modulation and Pseudoprogression." Immuno, vol. 6, no. 2, 2026, p. 40, https://doi.org/10.3390/immuno6020040.